Appeal No. 1996-2537
Application No. 08/102,654
following new ground of rejection.
Claim 2 is rejected under 35 U.S.C. § 102(b) as
anticipated by Ezure , as further evidenced by American1
Chemical Society File Registry No. RN 108147-54-2 and Legler.
Ezure describes the compound recited in claim 2 on
appeal. Ezure describes the synthesis of N-n-butyl-1-
deoxygalactostatin, and shows that the compound has $-
galactosidase inhibitory activity (Example 23 at page 29, and
Table 1 at page 31). This compound is also identified as N-
n-butyl-1,5-dideoxy-1,5-imino-D-galactitol or N-n-butyl-1-
deoxygalactonojirimycin. See File Registry No. RN 108147-54-
2, and Legler, page 120, lines 12, 18 and 19.
V. CONCLUSION
In conclusion, for the reasons set forth in the body of
this
opinion, we reverse the rejection of claim 2 under 35 U.S.C.
1Ezure is the Canadian equivalent of European Patent Application
0536402-A, cited on the form PTO-1449 filed Sep. 15, 1994, attached to Paper
No. 9.
7
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: November 3, 2007